## 3 Results  
For our study, we identified 90 BMA prescribers in our hospital. Out of these, 14 were excluded due to the lack of a valid email address or to their not being available for response \begin{table}
\begin{tabular}{l l} \hline \hline
**Questions** & **Possible Answers** \\ \hline  & Pamidronate (Aredia®) \\  & Risedronate (Actonel®) \\  & Ibandronate (Bonviva®) \\  & Teriparatide (Forsteo®) \\  & Alendronate (Fosamax®) \\  & \\ What specific bone modifying agents do & Alendronate (Fosamax®) \\  & Jou prescribe? & Denosumab (Prolia®) \\  & Sunitinib (Sutent®) \\  & Zolendronate (Zometa®) \\  & Tluidronate (Skelid®) \\  & Eidronate (Didrone®) \\  & Others \\ \hline Do you recommend a dental check-up for patients & Yes \\  & before initialing BMA treatment? & No \\ \hline  & Nausea, vomiting, diarrhea \\  & Headache \\  & Dyspine \\ Are you aware of the side effects that may occur & Kidney disease \\  & frequently following anti-resorptive treatments? & Musculoskeletal pain \\  & Osteonecrosis of the jaw \\  & Others \\ \hline Do you know the definition/term & Yes \\  & Medication-induced Osteonecrosis of the jaw? & No \\ \hline  & Bisphosphonate-related osteonecrosis of the \\  & jaw (BRON)] \\ Which definition is more familiar to you? & Medication-related osteonecrosis of the \\  & jaw (MRON)] \\  & Antiserotive drug related osteonecrosis of the \\  & jaw (ARON)] \\ \hline How many patients with MRONJ have you & 5–1 \\  & ever managed? & 10–5 \\  & \textgreater{}10 \\ \hline  & Sending the patient to OMF Surgeon \\ What type of management options did & Stopping the anti-resorptive treatment \\  & Prescribing antibiotics \\  & Preschromending Hyperbaric oxygen therapy \\  & Applying blood growth factors \\ \hline  & Oral bisphosphonates \\  & I.v. bisphosphonates \\  & Denosumab \\ For patients with MRONJ, for which drug do you & Parathormone \\  & Teriparatide \\  & Tyrosine Kinazis \\  & Others \\ \hline What is the usual drug withdrawal & \textless{}3 months \\ period recommended? & \textgreater{}3 months \\ \hline  & Dental cleaning \\ Which dental procedure do you recommend drug & Dental filling \\  & Dental extraction \\ withdrawal for? & Dental Implant insertion \\ \hline \hline \end{tabular}
\end{table} 
Table 2: \(Cont.\)during the time of the study, resulting in 76 possible participants. A total of 55 BMA prescribers from different medical fields considered relevant to our purpose, including rheumatologists, oncologists, endocrinologists, and general practitioners, answered our questionnaire, which constituted a response rate of 72% and an attainability rate of 61%. Most responders were female (77%), and the average age of the responders was 40 years old. Most were endocrinologists (45%) and senior physicians (37%), and experience of prescribing BMAs was relatively well-distributed. The composition of the physician cohort is presented in Table 3.  
The physicians usually prescribed BMAs for osteoporosis (83%) and osteopenia (67%), with bone metastases presenting as a less frequent indication for treatment (20%), followed by osteogenesis imperfecta (18%) and Paget's disease (15%). The most common BMAs prescribed were oral bisphosphonates (96%), followed by i.v. preparations (56%), with less than half using denosumab (42%) and teriparatide (35%) or other treatment options. The most commonly used medications for these patients were both second- and third-generation bisphosphonates, such as alendronate (Fosamax(r)) and ibandronate (Bonviya(r)), with other preparations being used far less frequently, such as denosumab (Prolia(r)) and teriparatide (Forsteo(r)), while sunitinib (Sutent(r)) was prescribed by even fewer physicians.